Four companies request CHMP second opinion
This article was originally published in Scrip
So far in 2014 the European medicines agency's committee for medicinal products for human use (CHMP) has returned four negative opinions for new medicines compared to 16 positive recommendations. However, all four companies who have been unsuccessful with the committee in the New Year have this month called for re-examinations of the decisions.
You may also be interested in...
Helsinn and AB Science plan to conduct additional studies with their products the CHMP turned down this month, in an effort to secure eventual EU approval in the rejected indications. A third company, XBiotech, hasn’t ruled out similar action. New MAAs would be required.
With more than 30 years’ experience in pharma and biotech, Clive Dix has seen the industry evolve and take on many challenges. He spoke to Scrip about his career journey, the future of biotech and his expectations for 2022 – another year under the cloud of COVID-19.
The annual J.P. Morgan Healthcare Conference saw major medtech companies describe their experiences in 2021 and expectations for 2022 as they continue to cope with COVID-19.